549 results about "Early rheumatoid arthritis" patented technology

The invention provides an application of parabacteroides merdae in treating or preventing rheumatoid arthritis or related diseases thereof, and also provides a pharmaceutical composition, a medicament, a food and a feed containing the parabacteroides merdae. By providing the parabacteroides merdae for animals, an anti-inflammatory effect can be effectively brought into play, the symptoms of rubefaction and swelling of joints can be effectively improved, and the symptoms of arthritis can be obviously relieved, so that the parabacteroides merdae can be effectively used for treating or preventing the rheumatoid arthritis or the related diseases thereof.

The invention provides application of bacteroides ovatus in treating or preventing rheumatoid arthritis or related diseases thereof, and further provides a pharmaceutical composition, a medicine, a food and feed containing the bacteroides ovatus. Applied to animals, the bacteroides ovatus can be used for effectively developing an anti-inflammatory efficacy, so that the symptom of redness and swelling of joint is effectively improved and the symptom of arthritis is remarkably relieved; and the bacteroides ovatus can be effectively used for treating or preventing rheumatoid arthritis or related diseases thereof.

The invention provides application of bacteroides thetaiotaomicron in treating or preventing rheumatoid arthritis or related diseases thereof, and further provides a pharmaceutical composition, a medicine, a food and feed containing the bacteroides thetaiotaomicron. Applied to animals, the bacteroides thetaiotaomicron can be used for effectively developing an anti-inflammatory efficacy, so that the symptom of redness and swelling of joint is effectively improved and the symptom of arthritis is remarkably relieved; and the bacteroides thetaiotaomicron can be effectively used for treating or preventing rheumatoid arthritis or related diseases thereof.

There is provided a synovial cell growth inhibitor, or a pharmaceutical composition for treatment of chronic rheumatoid arthritis based on the synovial cell growth inhibitor.

The pharmaceutical composition for treatment of chronic rheumatoid arthritis or synovial cell growth inhibitor contains an IL-6 antagonist, such as IL-6 antibody or IL-6R antibody, as an effective component.

A human T cell clone recognizing an antigen expressed by a synovial cell of a rheumatoid arthritis (RA) patient in HLA-DR-restricted manner is disclosed, which clone is very useful in exploring the pathogenesis of RA and developing a method for treating and preventing RA.

The invention provides application of bacteroides dorei in treating or preventing rheumatoid arthritis or related diseases thereof, and further provides a pharmaceutical composition, a medicine, a food and feed containing the bacteroides dorei. Applied to animals, the bacteroides dorei can be used for effectively developing an anti-inflammatory efficacy, so that the symptom of redness and swelling of joint is effectively improved and the symptom of arthritis is remarkably relieved; and the bacteroides dorei can be effectively used for treating or preventing rheumatoid arthritis or related diseases thereof.

The invention provides an application of bacteroides caccae in treatment or prevention of rheumatoid arthritis or related diseases thereof, and also provides bacteroides caccae containing pharmaceutical compositions, medicaments, foods and feeds. By providing bacteroides caccae for animals, an anti-inflammatory effect can be effectively played, the symptoms such as redness and swelling of joints are effectively improved, and the symptoms of arthritis are obviously relieved, and therefore, the bacteroides caccae can be effectively used for treating or preventing rheumatoid arthritis or related diseases thereof.

This invention provides a method of treating a subject afflicted with rheumatoid arthritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate, wherein the amounts when taken together are effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in combination with methotrexate in treating a subject afflicted with rheumatoid arthritis. This invention also provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof and an amount of methotrexate for use in treating a subject afflicted with rheumatoid arthritis.

Disclosed are compositions and methods for the treatment and/or prevention of rheumatoid arthritis, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof.

The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in the differential diagnosis of rheumatoid arthritis in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample both the concentration of anti-CCP and of antinuclear antibodies (ANA) correlating the concentrations determined to the diagnosis of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and ANA and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and ANA in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.

The invention relates to the molecular biology field and particularly relates to a gene knockout carrier, a construction method and application thereof and a gene knockout method of an NLRP1 gene of an MH7A cell. A CRISPR-Cas9 gene knockout system is utilized for carrying out CRISPR targeting sequence design by taking NLRP1 as a target gene so as to prepare a knockout carrier aiming at the NLRP1 gene, and the knockout carrier is utilized for transfecting the MH7A cell, so that the NLRP1 gene in the MH7A cell can be efficiently knocked out; and therefore, a research platform for rheumatoid arthritis is effectively built, so that the research of the pathogenesis of the rheumatoid arthritis is greatly promoted, and the researches of the interaction of NLRP1 inflammasomes and various inflammatory factors and the disease related molecular mechanisms of the rheumatoid arthritis and meningitis can be promoted.

The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., rheumatoid arthritis (RA) patients, e.g., high risk RA patients, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).

The invention discloses an epitope of rheumatoid arthritis and application thereof, belonging to the technical field of immunologic diagnosis. The epitope is a polypeptide, and the amino acid sequence is disclosed as SEQ ID NO:1 in the sequence table. ELISA detection and patient serum reaction condition indicate that the epitope polypeptide can be specifically combined with IgG in the patient serum, and does not react with the serum of a health person. The epitope polypeptide can be used for preparing medicines for diagnosing rheumatoid arthritis.

A composite medicine for treating the umatoid arthritis and autoimmune disease contains the sweet worm wood herb's extract (dihydroarteannuin, artesumate, artemether, etc).

The invention relates to a traditional Chinese medicine for treating rheumatoid arthritis. The traditional Chinese medicine consists of the following raw material medicaments by weight: 9 to 20 grams of incised notopterygium rhizome, 6 to 12 grams of divaricate saposhnikovia root, 3 to 9 grams of prepared liquoric root, 9 to 20 grams of heracleum, 9 to 30 grams of Chinese taxillus twig, 6 to 18 grams of root of largeleaf gentian, 9 to 18 grams of Chinese angelica, 6 to 9 grams of cassia twig, 6 to 18 grams of achyranthes root, 6 to 15 grams of turmeric, 9 to 30 grams of mulberry twig and 9 to 18 grams of eucommia bark. The traditional Chinese medicine of the invention has simple and reasonable formula, wide medicinal herbs resource, low cost, remarkable curative effect and clinical application effective rate of 83.2 percent, does not have toxic or side effect, and is convenient to use.

The present invention pertains, at least in part, to substituted tetracycline compounds. The present invention also pertains to methods for treating rheumatoid arthritis in a subject, comprising administering to the subject a tetracycline compound of the invention.

The invention provides methods for determining whether a subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene comprising contacting isolated fibroblasts from the subject with a molecule or pool of molecules directed to the BRAF oncogene; and culturing the sample in the presence of the agent and determining whether BRAF oncogene expression by the cell is decreased and/or whether cells in the sample return to a less transformed phenotype, exhibit decreased cell proliferation and/or exhibit increased contact inhibition, any of which is indicative that the subject is suffering from a rheumatoid arthritis associated with the BRAF oncogene.

This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.

Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).